Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment

References

• Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971–1993. Diabetes Care21(7), 1138–1145 (1998).
   PubMed Web of Science ®Google Scholar
• McGuire DK, Emanuelsson H, Granger CB et al.; GUSTO IIb Investigators. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. Eur. Heart J.21(21), 1750–1758 (2000).
   PubMed Web of Science ®Google Scholar
• McGuire DK, Newby LK, Bhapkar MV et al. Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. Am. Heart J.147(2), 246–252 (2004).
   PubMed Web of Science ®Google Scholar
• Brunner EJ, Shipley MJ, Witte DR, Fuller JH, Marmot MG. Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diabetes Care29(1), 26–31 (2006).
   PubMed Web of Science ®Google Scholar
• Muhlestein JB, Anderson JL, Horne BD et al. Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am. Heart J.146(2), 351–358 (2003).
   PubMed Web of Science ®Google Scholar
• Fox CS, Coady S, Sorlie PD et al. Trends in cardiovascular complications of diabetes. JAMA292(20), 2495–2499 (2004).
   PubMed Web of Science ®Google Scholar
• Kearney PM, Blackwell L, Collins R et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet371(9607), 117–125 (2008).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation110(2), 227–239 (2004).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2008. Diabetes Care31(Suppl. 1), S12–S54 (2008).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA289(19), 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Sacks FM, Hermans MP et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab. Vasc. Dis. Res.5(4), 319–335 (2008).
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med.358(24), 2545–2559 (2008).
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with Type 2 diabetes. N. Engl. J. Med.358(24), 2560–2572 (2008).
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with Type 2 diabetes. N. Engl. J. Med.360(2), 129–139 (2009).
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in Type 2 diabetes. N. Engl. J. Med.359(15), 1577–1589 (2008).
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet366(9500), 1849–1861 (2005).
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med.357(21), 2109–2122 (2007).
   PubMed Web of Science ®Google Scholar
• Natarajan A, Zaman AG, Marshall SM. Platelet hyperactivity in Type 2 diabetes: role of antiplatelet agents. Diab. Vasc. Dis. Res.5(2), 138–144 (2008).
   PubMed Web of Science ®Google Scholar
• Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in Type 2 diabetes. Diabetes Care24(8), 1476–1485 (2001).
   PubMed Web of Science ®Google Scholar
• Tschoepe D, Roesen P, Schwippert B, Gries FA. Platelets in diabetes: the role in the hemostatic regulation in atherosclerosis. Semin. Thromb. Hemost.19(2), 122–128 (1993).
   PubMed Web of Science ®Google Scholar
• Winocour PD. Platelet abnormalities in diabetes mellitus. Diabetes41(Suppl. 2), 26–31 (1992).
   PubMed Web of Science ®Google Scholar
• Erlinge D, Varenhorst C, Braun OO et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J. Am. Coll Cardiol.52(24), 1968–1977 (2008).
   PubMed Web of Science ®Google Scholar
• Evangelista V, de Berardis G, Totani L et al. Persistent platelet activation in patients with Type 2 diabetes treated with low doses of aspirin. J. Thromb. Haemost.5(11), 2197–2203 (2007).
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Malinin AI, Pokov A, Barsness G, Hanley DF. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the Plavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial. Am. Heart J.155(1), 93.e1–93.e7 (2008).
   Google Scholar
• Serebruany VL, Malinin AI, Pokov AN, Hanley DF. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with Type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial. Clin. Ther.30(2), 249–259 (2008).
   PubMed Web of Science ®Google Scholar
• Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J. Thromb. Haemost.1(7), 1575–1579 (2003).
   PubMed Web of Science ®Google Scholar
• Juhan-Vague I, Alessi MC, Joly P et al. Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response. Arteriosclerosis9(3), 362–367 (1989).
   PubMedGoogle Scholar
• Inui Y, Suehiro T, Kumon Y, Hashimoto K. Platelet volume and urinary prostanoid metabolites in non-insulin-dependent diabetes mellitus. J. Atheroscler Thromb.1(2), 108–112 (1994).
   PubMedGoogle Scholar
• Yilmaz MB, Cihan G, Guray Y et al. Role of mean platelet volume in triagging acute coronary syndromes. J. Thromb. Thrombolysis, 26(1), 49–54 (2008).
   PubMed Web of Science ®Google Scholar
• Halushka PV, Rogers RC, Loadholt CB, Colwell JA. Increased platelet thromboxane synthesis in diabetes mellitus. J. Lab. Clin. Med.97(1), 87–96 (1981).
   PubMed Web of Science ®Google Scholar
• Kwaan HC, Colwell JA, Cruz S, Suwanwela N, Dobbie JG. Increased platelet aggregation in diabetes mellitus. J. Lab. Clin. Med.80(2), 236–246 (1972).
   PubMed Web of Science ®Google Scholar
• Trovati M, Anfossi G, Massucco P et al. Insulin stimulates nitric oxide synthesis in human platelets and, through nitric oxide, increases platelet concentrations of both guanosine-3´, 5´-cyclic monophosphate and adenosine-3´, 5´-cyclic monophosphate. Diabetes46(5), 742–749 (1997).
   PubMed Web of Science ®Google Scholar
• Phillips DR, Law D, Scarborough RM. Glycoprotein IIb-IIIa in platelet aggregation: an emerging target for the prevention of acute coronary thrombotic occlusions. Arch. Pathol. Lab. Med.122(9), 811–812 (1998).
   PubMed Web of Science ®Google Scholar
• Tschoepe D, Roesen P, Kaufmann L et al. Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur. J. Clin. Invest.20(2), 166–170 (1990).
   PubMed Web of Science ®Google Scholar
• Omoto S, Nomura S, Shouzu A et al. Significance of platelet-derived microparticles and activated platelets in diabetic nephropathy. Nephron81(3), 271–277 (1999).
   PubMed Web of Science ®Google Scholar
• Diamant M, Nieuwland R, Pablo RF et al. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated Type 2 diabetes mellitus. Circulation106(19), 2442–2447 (2002).
   PubMed Web of Science ®Google Scholar
• Jennings LK, Haga JH, Slack SM. Differential expression of a ligand induced binding site (LIBS) by GP IIb-IIIa ligand recognition peptides and parenteral antagonists. Thromb. Haemost.84(6), 1095–1102 (2000).
   PubMed Web of Science ®Google Scholar
• Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care26(7), 2181–2188 (2003).
   PubMed Web of Science ®Google Scholar
• Winocour PD. Platelet turnover in advanced diabetes. Eur. J. Clin. Invest.24(Suppl. 1), 34–37 (1994).
   PubMed Web of Science ®Google Scholar
• Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur. Heart J.27(6), 647–654 (2006).
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med.360(4), 354–362 (2009).
   PubMed Web of Science ®Google Scholar
• Pontiggia L, Lassila R, Pederiva S et al. Increased platelet-collagen interaction associated with double homozygosity for receptor polymorphisms of platelet GPIa and GPIIIa. Arterioscler. Thromb. Vasc. Biol.22(12), 2093–2098 (2002).
   PubMed Web of Science ®Google Scholar
• Michos ED, Ardehali R, Blumenthal RS, Lange RA, Ardehali H. Aspirin and clopidogrel resistance. Mayo Clin. Proc.81(4), 518–526 (2006).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler. Thromb. Vasc. Biol.26(8), 1895–1900 (2006).
   PubMed Web of Science ®Google Scholar
• McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb. Haemost.88(5), 711–715 (2002).
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ324(7329), 71–86 (2002).
   PubMed Web of Science ®Google Scholar
• Smith SC Jr, Allen J, Blair SN et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation113(19), 2363–2372 (2006).
   PubMed Web of Science ®Google Scholar
• Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabetologia51(3), 385–390 (2008).
   PubMed Web of Science ®Google Scholar
• Gresner P, Dolnik M, Waczulikova I et al. Increased blood plasma hydrolysis of acetylsalicylic acid in Type 2 diabetic patients: a role of plasma esterases. Biochim. Biophys. Acta1760(2), 207–215 (2006).
   PubMed Web of Science ®Google Scholar
• ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA268(10), 1292–1300 (1992).
   PubMed Web of Science ®Google Scholar
• Colwell JA. Aspirin therapy in diabetes. Diabetes Care27(Suppl. 1), S72–S73 (2004).
   PubMedGoogle Scholar
• Buse JB, Ginsberg HN, Bakris GL et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation115(1), 114–126 (2007).
   PubMed Web of Science ®Google Scholar
• Ryden L, Standl E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur. Heart J.28(1), 88–136 (2007).
   PubMed Web of Science ®Google Scholar
• v L, Zanchetti A, Carruthers SG et al.; the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet351(9118), 1755–1762 (1998).
   PubMed Web of Science ®Google Scholar
• Harpaz D, Gottlieb S, Graff E et al.; Israeli Bezafibrate Infarction Prevention Study Group. Effects of aspirin treatment on survival in non-insulin-dependent diabetic patients with coronary artery disease. Am. J. Med.105(6), 494–499 (1998).
   PubMed Web of Science ®Google Scholar
• Cubbon RM, Gale CP, Rajwani A et al. Aspirin and mortality in patients with diabetes sustaining acute coronary syndrome. Diabetes Care31(2), 363–365 (2008).
   PubMed Web of Science ®Google Scholar
• Sacco M, Pellegrini F, Roncaglioni MC et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in Type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care26(12), 3264–3272 (2003).
   PubMed Web of Science ®Google Scholar
• Belch J, MacCuish A, Campbell I et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ337, a1840 (2008).
   PubMed Web of Science ®Google Scholar
• Ogawa H, Nakayama M, Morimoto T et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with Type 2 diabetes: a randomized controlled trial. JAMA300(18), 2134–2141 (2008).
   PubMed Web of Science ®Google Scholar
• De Berardis G, Sacco M, Evangelista V et al.; ACCEPT-D Study Group. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials8, 21 (2007).
   PubMed Web of Science ®Google Scholar
• The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N. Engl. J. Med.338(21), 1498–1505 (1998).
   PubMed Web of Science ®Google Scholar
• The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Angina Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N. Engl. J. Med.338(21), 1488–1497 (1998).
   PubMed Web of Science ®Google Scholar
• The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N. Engl. J. Med.339(7), 436–443 (1998).
   PubMed Web of Science ®Google Scholar
• O’Shea JC, Hafley GE, Greenberg S et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA285(19), 2468–2473 (2001).
   PubMed Web of Science ®Google Scholar
• The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet349, 1429–1435 (1997).
   PubMed Web of Science ®Google Scholar
• Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet357(9272), 1915–1924 (2001).
   PubMed Web of Science ®Google Scholar
• The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N. Engl. J. Med.330(14), 956–961 (1994).
   PubMed Web of Science ®Google Scholar
• Topol EJ, Moliterno DJ, Herrmann HC et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N. Engl. J. Med.344(25), 1888–1894 (2001).
   PubMed Web of Science ®Google Scholar
• Roffi M, Chew DP, Mukherjee D et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation104(23), 2767–2771 (2001).
   PubMed Web of Science ®Google Scholar
• Anderson JL, Adams CD, Antman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons; endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation116(7), e148–e304 (2007).
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Marso SP, Lincoff AM et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J. Am. Coll Cardiol.35(4), 922–928 (2000).
   PubMed Web of Science ®Google Scholar
• Labinaz M, Madan M, O’Shea JO et al. Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial). Am. J. Cardiol.90(6), 585–590 (2002).
   PubMed Web of Science ®Google Scholar
• Mehilli J, Kastrati A, Schuhlen H et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation110(24), 3627–3635 (2004).
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet348(9038), 1329–1339 (1996).
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Marso SP, Hirsch AT et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am. J. Cardiol.90(6), 625–628 (2002).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med.345(7), 494–502 (2001).
   PubMed Web of Science ®Google Scholar
• Beinart SC, Kolm P, Veledar E et al. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J. Am. Coll. Cardiol.46(5), 761–769 (2005).
   PubMed Web of Science ®Google Scholar
• Chen ZM, Jiang LX, Chen YP et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet366(9497), 1607–1621 (2005).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Shoemaker SB, Desai B et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation115(6), 708–716 (2007).
   PubMed Web of Science ®Google Scholar
• Alfonso F, Angiolillo DJ. Platelet function assessment to predict outcomes after coronary interventions: hype or hope? J. Am. Coll. Cardiol.48(9), 1751–1754 (2006).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ. Tackling the diabetic platelet: is high clopidogrel dosing the answer? J. Thromb. Haemost.4(12), 2563–2565 (2006).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Capranzano P, Desai B et al. Impact of P2Y12 inhibitory effects induced by clopidogrel on platelet procoagulant activity in Type 2 diabetes mellitus patients. Thromb. Res. DOI: 10.1016/j.thromres.2008.10.001 (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Platelet function profiles in patients with Type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes54(8), 2430–2435 (2005).
   PubMed Web of Science ®Google Scholar
• Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc. Drug Rev.25(4), 357–374 (2007).
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, Angiolillo DJ et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation118(16), 1626–1636 (2008).
   PubMed Web of Science ®Google Scholar